DALLAS--(BUSINESS WIRE)--Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that it has commenced discussions pertaining to representation of the Company in Poland for the purpose of Clinical Testing of the Company’s Medical Device for the treatment of Alzheimer’s Disease utilizing the Omentum. The purpose of these discussions are to engage consultants to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company’s prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach to the treatment for patients suffering from Alzheimer’s and Dementia.
Help employers find you! Check out all the jobs and post your resume.
